Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1957 1
1968 1
1984 1
1985 1
1993 1
1998 2
1999 2
2002 2
2003 3
2006 1
2007 1
2010 3
2011 3
2013 1
2015 1
2017 2
2018 3
2019 1
2020 4
2021 5
2022 1
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Surgical management of lung metastases.
Patrini D, Panagiotopoulos N, Lawrence D, Scarci M. Patrini D, et al. Br J Hosp Med (Lond). 2017 Apr 2;78(4):192-198. doi: 10.12968/hmed.2017.78.4.192. Br J Hosp Med (Lond). 2017. PMID: 28398890 Review.
Management of pulmonary metastases has evolved considerably over the last few decades but is still controversial. The surgical management of lung metastases is outlined, discussing the preoperative management, indications for surgery, the surgical approach and outcomes acc …
Management of pulmonary metastases has evolved considerably over the last few decades but is still controversial. The surgical management of …
Lenvatinib in Management of Solid Tumors.
Hao Z, Wang P. Hao Z, et al. Oncologist. 2020 Feb;25(2):e302-e310. doi: 10.1634/theoncologist.2019-0407. Epub 2019 Oct 14. Oncologist. 2020. PMID: 32043789 Free PMC article. Review.
Lenvatinib is a type I tyrosine kinase inhibitor exhibiting powerful antiangiogenic activity in cancer therapy. Displaying activity in multiple solid tumors, it has been approved in differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma …
Lenvatinib is a type I tyrosine kinase inhibitor exhibiting powerful antiangiogenic activity in cancer therapy. Displaying activity i …
Prognosis and management of recurrent and/or metastatic head and neck adenoid cystic carcinoma.
Lorini L, Ardighieri L, Bozzola A, Romani C, Bignotti E, Buglione M, Guerini A, Lombardi D, Deganello A, Tomasoni M, Bonini SA, Sigala S, Farina D, Ravanelli M, Bossi P. Lorini L, et al. Oral Oncol. 2021 Apr;115:105213. doi: 10.1016/j.oraloncology.2021.105213. Epub 2021 Feb 9. Oral Oncol. 2021. PMID: 33578204 Review.
Adenoid cystic carcinoma (ACC) is a rare tumor, usually arising in the salivary gland, accounting for 1% of all head and neck cancers. ...This review critically analyzes pathological and molecular prognostic factors in RM ACC and make an overview on actual …
Adenoid cystic carcinoma (ACC) is a rare tumor, usually arising in the salivary gland, accounting for 1% of all head an …
Adenoid Cystic Carcinoma, Clinical Presentation, Current Treatment and Approaches Towards Novel Therapies.
Zupancic M, Näsman A, Friesland S, Dalianis T. Zupancic M, et al. Anticancer Res. 2024 Apr;44(4):1325-1334. doi: 10.21873/anticanres.16929. Anticancer Res. 2024. PMID: 38537991 Review.
Adenoid cystic carcinoma (AdCC) is a rare cancer originating from secretory glands with unknown aetiology. ...Moreover, there is a lack of good prognostic markers, and due to its rarity, it is difficult to predict which therapeutic methods are the most …
Adenoid cystic carcinoma (AdCC) is a rare cancer originating from secretory glands with unknown aetiology. ...Moreover, …
Current diagnosis and treatment of salivary gland-type tumors of the lung.
Horio Y, Kuroda H, Masago K, Matsushita H, Sasaki E, Fujiwara Y. Horio Y, et al. Jpn J Clin Oncol. 2024 Mar 9;54(3):229-247. doi: 10.1093/jjco/hyad160. Jpn J Clin Oncol. 2024. PMID: 38018262 Review.
In the last 20 years, several genetic rearrangements have been identified, such as MYB::NF1B rearrangements in adenoid cystic carcinoma, CRTC1::MAML2 rearrangements in mucoepidermoid carcinoma, EWSR1::ATF1 rearrangements in hyalinizing clear cell ca …
In the last 20 years, several genetic rearrangements have been identified, such as MYB::NF1B rearrangements in adenoid cystic …
Management of nasopharyngeal adenoid cystic carcinoma.
Cao CN, Luo JW, Xu GZ, Gao L, Xu ZG, Tang PZ. Cao CN, et al. J Oral Maxillofac Surg. 2013 Apr;71(4):e203-9. doi: 10.1016/j.joms.2012.12.024. J Oral Maxillofac Surg. 2013. PMID: 23507327
PURPOSE: Nasopharyngeal adenoid cystic carcinomas (NACCs) are rare. No clear consensus is available regarding clinical characteristics and management approaches. ...CONCLUSIONS: NACC is a malignancy with a generally favorable prognosis. Radiotherapy alone or a combi …
PURPOSE: Nasopharyngeal adenoid cystic carcinomas (NACCs) are rare. No clear consensus is available regarding clinical charact …
Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma.
Xu MJ, Wu TJ, van Zante A, El-Sayed IH, Algazi AP, Ryan WR, Ha PK, Yom SS. Xu MJ, et al. J Otolaryngol Head Neck Surg. 2018 Apr 25;47(1):28. doi: 10.1186/s40463-018-0273-z. J Otolaryngol Head Neck Surg. 2018. PMID: 29695289 Free PMC article.
BACKGROUND: Management of locoregional recurrence (LRR) and distant metastasis (DM) in adenoid cystic carcinoma (ACC) is guided by limited data. We investigated mortality risks in patients diagnosed and treated for recurrent ACC. ...Among DM patients, six wer …
BACKGROUND: Management of locoregional recurrence (LRR) and distant metastasis (DM) in adenoid cystic carcinoma (ACC) i …
Clinical features, treatment and outcomes in patients with tracheal adenoid cystic carcinoma: a systematic literature review.
Ran J, Qu G, Chen X, Zhao D. Ran J, et al. Radiat Oncol. 2021 Feb 19;16(1):38. doi: 10.1186/s13014-021-01770-0. Radiat Oncol. 2021. PMID: 33608038 Free PMC article.
BACKGROUND: Primary tracheal adenoid cystic carcinoma (TACC) is rare and originates from the minor salivary gland. Biologically, TACC results in delayed presentation, and the therapeutic effects of multimodal treatment differ across individuals. ...
BACKGROUND: Primary tracheal adenoid cystic carcinoma (TACC) is rare and originates from the minor salivary gland. Biol …
Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US.
Elimimian EB, Samuel TA, Liang H, Elson L, Bilani N, Nahleh ZA. Elimimian EB, et al. JAMA Netw Open. 2021 Apr 1;4(4):e214123. doi: 10.1001/jamanetworkopen.2021.4123. JAMA Netw Open. 2021. PMID: 33844001 Free PMC article.
The 5-year OS rate was superior for patients with medullary (91.7%) and adenoid cystic carcinoma (88.4%) compared with patients with metaplastic carcinoma (63.1%). The 5-year mortality rate for adenoid cystic carcinoma was 8.33% vs …
The 5-year OS rate was superior for patients with medullary (91.7%) and adenoid cystic carcinoma (88.4%) compared with …
Photodynamic therapy for primary tracheobronchial malignancy in Northwestern China.
Zhang Q, Zheng K, Gu X, Gao Y, Zhao S, Zhang H, Wang Z, Li W, Liu W, Nan Y, Liu G, Jin F. Zhang Q, et al. Photodiagnosis Photodyn Ther. 2022 Mar;37:102701. doi: 10.1016/j.pdpdt.2021.102701. Epub 2021 Dec 23. Photodiagnosis Photodyn Ther. 2022. PMID: 34954091 Free article.
However, the experience in tracheobronchial adenoid cystic carcinoma (ACC) and peripheral lung cancer is still insufficient. This study aimed to share the experience of PDT for patients with primary tracheobronchial malignancy, especially the adenoi …
However, the experience in tracheobronchial adenoid cystic carcinoma (ACC) and peripheral lung cancer is still i …
40 results